FOUND: Msd - You Need To See This

New Zealand announces major overhaul of seasonal worker scheme; changes from 2027

New Zealand's Recognised Seasonal Employer scheme will see reforms starting in 2027. These changes aim to simplify recruitment and improve worker protections for overseas staff. Employers will experience streamlined accreditation and agreement processes under the new framework. Workers will benefit from strengthened support and clearer cost recovery agreements. The government…

The Economic Times · Aug 1

Merck-Backed Lab Gets $8.5 Million to Fast-Track a Vaccine for a Rapidly Spreading Ebola Outbreak

Hilleman Laboratories, a Singapore-based joint venture of Merck & Co. Inc. (NYSE:MRK) MSD division and Wellcome, said Thursday it will develop and manufacture clinical trial doses of an investigational Bundibugyo Ebola vaccine with up to $8.5 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI).

Benzinga · Jul 30

New NHS cancer jab means treatment could take minutes rather than hours

Until now, patients have had to spend hours on a drip to get the drug pembrolizumab (Keytruda) to treat their cancer.

The Independent UK · May 3

UK set on resolving standoff with big pharma, science minister says

Patrick Vallance says relations must improve and NHS has to reverse decline in drugs investment

The Guardian - UK · Sep 16, 2025

UK ‘difficult’ operating environment says Merck boss after £1bn London site axed

Last week, Merck’s business in the UK and Europe, MSD, said it will move its life sciences operation to the US, impacting around 125 British jobs.

Evening Standard · Sep 16, 2025

Big pharma firms have paused nearly £2bn in UK investments this year

Government’s plans in disarray before Trump talks as MSD, Eli Lilly and AstraZeneca moves prompt job fears

The Guardian - UK · Sep 16, 2025

Merck’s move to axe £1bn UK expansion was ‘commercial decision’, says minister

The Conservatives said Merck’s decision should send alarm bells ringing across Government.

Evening Standard · Sep 11, 2025

Pharma giant ditches £1bn London research hub and says UK ‘is not internationally competitive’

Merck, known as MSD in Europe, criticised the UK’s business environment despite the government saying it has become ‘the most attractive place to invest in the world’

The Independent UK · Sep 11, 2025

US drugmaker Merck scraps £1bn London research centre and cuts 125 science jobs

New blow to UK’s key life science sector as industry body says country is losing ground on investment and research

The Guardian - UK · Sep 10, 2025

‘Touch and go’: Reading stuck in brinkmanship battle over sale as deadline looms

Reading are trapped in a three-way battle of brinkmanship involving owner Dai Yongge and two potential buyers, leaving staff at the club fearing they will be forced into administration next month.

The Guardian - UK · Mar 25, 2025